| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2018 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ELEVEN BIOTHERAPEUTICS INC | 7 | Q3 2015 | 13.9% |
| Foundation Medicine, Inc. | 6 | Q1 2015 | 44.6% |
| SAGE THERAPEUTICS INC | 5 | Q3 2015 | 66.7% |
| Agios Pharmaceuticals, Inc. | 5 | Q4 2014 | 38.6% |
| bluebird bio, Inc. | 5 | Q4 2014 | 22.4% |
| ZAFGEN INC | 5 | Q3 2015 | 17.8% |
| BLUEPRINT MEDICINES CORP | 2 | Q3 2015 | 20.4% |
| GLOBAL BLOOD THERAPEUTICS IN | 1 | Q3 2015 | 58.1% |
View Third Rock Ventures, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2015-11-03 |
| 13F-HR | 2015-07-30 |
| 13F-HR | 2015-04-29 |
| 13F-HR | 2015-01-26 |
| 13F-HR | 2014-10-22 |
| 13F-HR | 2014-07-30 |
| 13F-HR | 2014-04-30 |
| 13F-HR | 2014-02-14 |
View Third Rock Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.